Chronic HD responds to bexarotene gel

July 1, 2004

Portland, OR - In a small study of bexarotene gel treatment for chronic severe hand dermatitis (HD), the medication achieved both speedy and surprising results. In a 55-patient, phase 1-2 open-label randomized clinical study of the gel, used alone and in combination with one of two steroids, 79 percent of patients on monotherapy achieved clinical improvement of at least 50 percent, and 39 percent reached at least 90 percent clearance.